# Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

> **NCT03348904** · PHASE3 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 2 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Epacadostat
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03348904
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-27
- **Primary completion:** 2018-05-22
- **Final completion:** 2018-05-22
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
- **Last updated:** 2019-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03348904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03348904, "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03348904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*